更多...
收起
This gene encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor (GPCR) superfamily, which is subdivided into classes and subtypes. The receptors are seven-pass transmembrane proteins that respond to extracellular cues and activate intracellular signal transduction pathways. This protein, an adenosine receptor of A2A subtype, uses adenosine as the preferred endogenous agonist and preferentially interacts with the G(s) and G(olf) family of G proteins to increase intracellular cAMP levels. It plays an important role in many biological functions, such as cardiac rhythm and circulation, cerebral and renal blood flow, immune function, pain regulation, and sleep. It has been implicated in pathophysiological conditions such as inflammatory diseases and neurodegenerative disorders. Alternative splicing results in multiple transcript variants. A read-through transcript composed of the upstream SPECC1L (sperm antigen with calponin homology and coiled-coil domains 1-like) and ADORA2A (adenosine A2a receptor) gene sequence has been identified, but it is thought to be non-coding. [provided by RefSeq, Jun 2013]
[中文简述(自动翻译):]  这个基因编码被细分为类和亚型的鸟嘌呤核苷酸结合蛋白(G蛋白)偶联的受体(GPCR)超家族的一个成员。该受体是细胞外线索响应并激活细胞内信号转导途径七次跨膜蛋白。这种蛋白质,A2A亚型的腺苷受体,使用腺苷作为首选的内源性激动剂和优先与G(S)和G蛋白的G(OLF)家族相互作用,以提高细胞内cAMP水平。它在许多生物学功能,如心脏节律和循环,脑和肾血流量,免疫功能,疼痛调节和睡眠中起重要作用。它已牵涉在病理生理条件,如炎性疾病和神经变性疾病。替代拼接结果在多个抄本变形。的只读通过转录上游SPECC1L组成(具有调宁蛋白同源精子抗原和卷曲螺旋结构域1-等)和ADORA2A(腺苷A2A受体)的基因序列已被确定,但是它被认为是无编码。 [由RefSeq的,2013年6月提供]
ADORA2A基因(以及对应的蛋白质)的细胞分布位置:
ADORA2A基因的本体(GO)信息:
| 疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
| Panic Disorder | 0.134178448 | 8 | 1 | BeFree_CTD_human_GAD_LHGDN |
| Anxiety Disorders | 0.125081451 | 12 | 2 | BeFree_CTD_human_GAD |
| Rheumatoid Arthritis | 0.125005506 | 3 | 0 | BeFree_CTD_human_GAD |
| Drug Allergy | 0.122367032 | 1 | 0 | CTD_human_GAD |
| Sleep Initiation and Maintenance Disorders | 0.122367032 | 2 | 0 | CTD_human_GAD |
| Psychoses, Substance-Induced | 0.122367032 | 1 | 0 | CTD_human_GAD |
| Amphetamine-Related Disorders | 0.122367032 | 1 | 0 | CTD_human_GAD |
| Seizures | 0.120271442 | 2 | 0 | BeFree_CTD_human |
| Hypotension | 0.12 | 3 | 0 | CTD_human |
| Liver Cirrhosis, Experimental | 0.12 | 1 | 0 | CTD_human |
| Substance Withdrawal Syndrome | 0.12 | 3 | 0 | CTD_human |
| Tremor | 0.12 | 1 | 0 | CTD_human |
| Adverse reaction to drug | 0.12 | 1 | 0 | CTD_human |
| Ventricular Dysfunction | 0.12 | 1 | 0 | CTD_human |
| Hyperactive behavior | 0.12 | 1 | 0 | CTD_human |
| Cardiomyopathies | 0.12 | 1 | 0 | CTD_human |
| Diabetes Mellitus, Experimental | 0.08 | 1 | 0 | RGD |
| Lung diseases | 0.08 | 2 | 0 | RGD |
| Reperfusion Injury | 0.08 | 1 | 0 | RGD |
| MYOPIA 2 (disorder) | 0.08 | 0 | 0 | MGD |
| Idiopathic pulmonary arterial hypertension | 0.08 | 0 | 0 | MGD |
| Huntington Disease | 0.008001298 | 4 | 0 | BeFree_GAD_LHGDN |
| Asthma | 0.007815732 | 3 | 0 | GAD_LHGDN |
| Syncope | 0.005362824 | 2 | 0 | BeFree_GAD_LHGDN |
| Sleep Disorders | 0.004734064 | 2 | 0 | GAD |
| Schizophrenia | 0.003995683 | 6 | 0 | BeFree_GAD |
| Fibrosis | 0.00272435 | 1 | 0 | LHGDN |
| Ischemia | 0.00272435 | 1 | 0 | LHGDN |
| Chronic Obstructive Airway Disease | 0.00272435 | 1 | 0 | LHGDN |
| Autistic Disorder | 0.002638474 | 1 | 0 | BeFree_GAD |
| Hypertensive disease | 0.002638474 | 2 | 0 | BeFree_GAD |
| Parkinson Disease | 0.002638474 | 2 | 0 | BeFree_GAD |
| Mood Disorders | 0.002638474 | 1 | 0 | BeFree_GAD |
| Atherosclerosis | 0.002367032 | 1 | 0 | GAD |
| Fatigue | 0.002367032 | 1 | 0 | GAD |
| Weight Gain | 0.002367032 | 1 | 0 | GAD |
| Chronic progressive chorea | 0.002367032 | 1 | 0 | GAD |
| Weight Gain Adverse Event | 0.002367032 | 1 | 0 | GAD |
| PANIC DISORDER 1 | 0.001628651 | 6 | 1 | BeFree |
| Dyskinetic syndrome | 0.000542884 | 2 | 0 | BeFree |
| Lingual-Facial-Buccal Dyskinesia | 0.000542884 | 2 | 0 | BeFree |
| Renal interstitial fibrosis | 0.000542884 | 2 | 0 | BeFree |
| Tardive Dyskinesia | 0.000542884 | 2 | 0 | BeFree |
| Agoraphobia | 0.000271442 | 1 | 0 | BeFree |
| Alzheimer's Disease | 0.000271442 | 1 | 0 | BeFree |
| Cardiomyopathy, Dilated | 0.000271442 | 1 | 0 | BeFree |
| Dementia, Vascular | 0.000271442 | 1 | 0 | BeFree |
| Epidermodysplasia Verruciformis | 0.000271442 | 1 | 0 | BeFree |
| Headache | 0.000271442 | 1 | 1 | BeFree |
| Heart failure | 0.000271442 | 1 | 0 | BeFree |
| Congestive heart failure | 0.000271442 | 1 | 0 | BeFree |
| Hodgkin Disease | 0.000271442 | 1 | 0 | BeFree |
| Lesch-Nyhan Syndrome | 0.000271442 | 1 | 0 | BeFree |
| Myopia | 0.000271442 | 1 | 0 | BeFree |
| Systemic Scleroderma | 0.000271442 | 1 | 0 | BeFree |
| Status Epilepticus | 0.000271442 | 1 | 0 | BeFree |
| Essential Hypertension | 0.000271442 | 1 | 0 | BeFree |
| Encephalopathies | 0.000271442 | 1 | 0 | BeFree |
| Migraine Disorders | 0.000271442 | 1 | 0 | BeFree |
| Obstructive nephropathy | 0.000271442 | 1 | 0 | BeFree |
| Migraine with Aura | 0.000271442 | 1 | 0 | BeFree |
| Fibrosis, Liver | 0.000271442 | 1 | 0 | BeFree |
| Carcinoma, Lewis Lung | 0.000271442 | 1 | 0 | BeFree |
| Chronic heart failure | 0.000271442 | 1 | 0 | BeFree |
| Solid tumour | 0.000271442 | 1 | 0 | BeFree |
| Phobic anxiety disorder | 0.000271442 | 1 | 1 | BeFree |
| Abnormal involuntary movement | 0.000271442 | 1 | 0 | BeFree |
| Neurodegenerative Disorders | 0.000271442 | 1 | 0 | BeFree |
| inflammatory joint disease | 0.000271442 | 1 | 0 | BeFree |
| Sleeplessness | 0.000271442 | 1 | 0 | BeFree |
| Autism Spectrum Disorders | 0.000271442 | 1 | 0 | BeFree |
忘记密码? 点击找回密码.
扫一扫右方二维码,关注微信订阅号,实时查看信息,关注医学生物学动态。